about
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaSerum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Bortezomib in patients with renal impairment.Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.The kidney in oncology.European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.A rare case of renal recovery in a young patient with multiple myelomaBenefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.Renal failure in multiple myeloma: a medical emergency.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?Current therapeutic strategy for multiple myeloma.Current treatments for renal failure due to multiple myeloma.Onco-nephrology: current concepts and future perspectives.Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors.Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.Multiple myeloma and diabetes.Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.
P2860
Q28067148-C581530D-F9F9-49BC-A0C3-D4D63C72A8DCQ33371085-60057C01-41ED-4B9F-93D1-9713FA2228A9Q33374368-E12064B5-16B4-47CF-A687-4C32FCDD7815Q33376918-97EF2F28-1447-4A07-9645-7223333197FBQ33396250-CE41E239-0FCE-4362-BC1D-34404347D8F0Q33397490-9B648659-5A99-4C1C-A1F7-1A9C8D6BD803Q33398587-2D32BBBC-CD73-4A98-AB48-1E3100A23A3DQ33400871-85677930-932A-4F4D-95C1-304DF02819E5Q33710330-16061D51-285C-460F-A03C-70C0D1297C98Q33730876-7DEBEE81-A3F9-4813-890F-92CEFD712101Q33874209-A46A83A8-6E99-4B9B-A3D4-67AED4815AA9Q35244883-CEA07579-4EB3-4C33-8525-88065C6463B3Q35603608-B8EAE333-1B3C-43BE-B6EF-E0779CB42684Q36033448-0C4662A2-2C3E-444C-B06A-59E60DEBCF12Q36088601-CE0FD0E5-37C6-4987-AE09-2C49273A0C17Q36301287-50C4B8E9-341A-4487-B25E-2775D835250AQ36900332-AB9C53E4-DF84-423D-8AB9-573850B0EC15Q36930970-4B0ABDF2-B3A4-4CF7-AD45-4B159D7CF5E2Q37157442-B0AAED2B-CEC2-495B-A62A-25D4DBA59322Q37556243-C71DFB0F-BDC9-4D68-A98F-6C5912311353Q37820338-CD2B662E-812E-49F6-B0BC-29C587F5DE3AQ37845643-7481E8A8-9DA7-46AF-949E-E70D8F291DD6Q37978343-AA7B36B9-06AE-451D-A8F7-45C0E8E4BD3BQ37986358-29EAFCA6-9B65-4B4B-824D-4A5CD703793CQ38021620-A1632B2E-3B44-4F38-9486-AC59FB28D4BFQ38072022-FE88CC5D-83BC-4E17-B5F1-A6ACB5049EB5Q38109235-A05D414E-0B49-4A50-9AD2-1DCB72A75A43Q38382457-2FFFE540-F8E8-4728-AFE5-A6796C302CCBQ38466621-6B05D9BC-2B6A-4C1B-A25E-4404A2699092Q38976968-001A97C2-3E77-4CA7-B724-35DDE858A636Q39692801-1DCED8D7-D297-41A6-8D46-EF1E9F345084Q40006468-4469873E-4FF8-45A2-B366-03305DE9EA2CQ40299548-38DD3F6D-FFF2-486E-BF8C-9416613CD4CBQ40468678-9F9C2392-990A-4DDC-882A-816D368D61B8Q40550022-F4BB1A67-5888-4EBA-AEAA-1D29A67551E1Q40626336-E8416731-38E5-4C34-9EB8-986B4941CDCFQ40718791-2F1D4FE9-CB7A-4F40-9A37-A58D6C151A2BQ40975758-16842A61-DC62-4B94-AD34-7DF088A8AF3FQ41080072-C23D95D5-2D97-4A38-A2CC-23F5A9ECD18CQ41714892-70C43862-E386-4E16-A0B8-B59951A747C1
P2860
description
im September 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 1998
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 1998
@uk
name
Renal Failure in Multiple Myeloma
@en
Renal Failure in Multiple Myeloma
@nl
type
label
Renal Failure in Multiple Myeloma
@en
Renal Failure in Multiple Myeloma
@nl
prefLabel
Renal Failure in Multiple Myeloma
@en
Renal Failure in Multiple Myeloma
@nl
P2093
P1476
Renal failure in multiple myel ...... ents from a single institution
@en
P2093
E Montserrat
J Montolíu
P Fernández-Llama
P304
P356
10.1001/ARCHINTE.158.17.1889
P407
P50
P577
1998-09-01T00:00:00Z